Covaxin 81% effective, works against UK variant, says Bharat Biotech
major Bharat Biotech on Wednesday said its Covid-19 vaccine, Covaxin, has demonstrated an interim vaccine efficacy of 81...
You are offline
India’s homegrown Covid-19 vaccine, Covaxin, generates immune responses against the fast-spreading coronavirus variant from the UK, scientists said on Wednesday after a study that they say should dispel speculation that the mutant might evade vaccine-generated antibodies.The study at the National Institute of Virology, Pune, has found that antibodies generated by Covaxin “neutralise†the UK variant that displays multiple mutations and had stirred concerns in some scientific circles that it might be able to resist effects of vaccines.The NIV researchers collaborating with the vaccine maker Bharat Biotech extracted sera from 38 recipients of Covaxin and observed through lab experiments that the vaccine-generated antibodies were able to neutralise the UK variant as efficiently as other novel coronavirus variants.
Related Notices
New Zealand in coronavirus lockdown as U.K. variant cases reported
The lockdown, which extends through Wednesday, is the first in New Zealand in six months and represents a significant se...
Experts Explain: Viruses, their variants, and vaccines
Over the past week, significant new research has been published on the variants of the novel coronavirus that have emerg...
This notice has been removed
The content is no longer available
Covaxin works on coronavirus variant from UK
India’s homegrown Covid-19 vaccine, Covaxin, generates immune responses against the fast-spreading coronavirus variant from the UK, scientists said on Wednesday after a study that they say should dispel speculation that the mutant might evade vaccine-generated antibodies.The study at the National Institute of Virology, Pune, has found that antibodies generated by Covaxin “neutralise†the UK variant that displays multiple mutations and had stirred concerns in some scientific circles that it might be able to resist effects of vaccines.The NIV researchers collaborating with the vaccine maker Bharat Biotech extracted sera from 38 recipients of Covaxin and observed through lab experiments that the vaccine-generated antibodies were able to neutralise the UK variant as efficiently as other novel coronavirus variants.
Recent Searches
Recent Noticeboards
Trending
No results found
Try a different search term
Something went wrong
No notices yet
No notices match these filters
Couldn't load notices
You're all caught up 🎉
Discussion (0)
No comments yet